Anuh Pharma Ltd
Anuh Pharma Ltd Q3 FY26 Results & Presentation Highlights: Revenue ₹201.18 Cr, PAT ₹13.45 Cr
Q3 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Anuh Pharma Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q3 FY26 Revenue: ₹201.18 Cr (page 13: Operating Revenue 197.18 + possibly rounding difference clarified on page 6 as ₹201 Cr) - Q3 FY25 Revenue: Not explicitly stated for Q3 FY25, but 9M FY25 total was ₹463.38 Cr (page 13) - Q3 FY26 vs Q3 FY25 Year-on-Year (YoY) % change not explicitly stated, but 9M FY26 revenue increased by 22.91% YoY to ₹569.54 Cr from ₹463.38 Cr (page 13) - Quarter-on-Quarter (QoQ) revenue growth from Q2 FY26 to Q3 FY26: 6.08% (₹197.18 Cr to ₹201.18 Cr) (page 13, page 6) - Outlook: Company anticipates steady growth rate of 15-16% per annum (page 33) - Commentary (page 6): "Revenue sustained strong momentum" and outlook expects year-end as per budget estimates with improving pricing, capacity expansion, higher utilization, and operational efficiencies driving sustainable margin improvements (pages 6 & 7). EBITDA (Q3 FY26): ₹20.91 Cr, up 62.63% QoQ (from ₹12.86 Cr) - Operating Margin (Q3 FY26): 23.28% (stated on Page 6), compared to 22.24% in the previous quarter - Profit After Tax (PAT, Q3 FY26): ₹13.45 Cr, up 76.70% QoQ (from ₹7.61 Cr) - Year-on-Year (9M FY26 vs 9M FY25) figures (Page 13): - EBITDA down 5.66% YoY to ₹47.45 Cr (from ₹50.29 Cr) - PAT down 15.85% YoY to ₹29.36 Cr (from ₹34.89 Cr) - Explicit Margin Outlook (Page 7 & 34): - Expectation of sustainable margin improvement driven by capacity expansion, higher utilization, operational efficiencies, improved pricing, and cost optimization.
From Anuh Pharma Ltd's Q3 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q3 FY26 Revenue: ₹201.18 Cr (page 13: Operating Revenue 197.18 + possibly rounding difference clarified on page 6 as ₹201 Cr)
- Q3 FY25 Revenue: Not explicitly stated for Q3 FY25, but 9M FY25 total was ₹463.38 Cr (page 13)
- Q3 FY26 vs Q3 FY25 Year-on-Year (YoY) % change not explicitly stated, but 9M FY26 revenue increased by 22.91% YoY to ₹569.54 Cr from ₹463.38 Cr (page 13)
- Quarter-on-Quarter (QoQ) revenue growth from Q2 FY26 to Q3 FY26: 6.08% (₹197.18 Cr to ₹201.18 Cr) (page 13, page 6)
- Outlook: Company anticipates steady growth rate of 15-16% per annum (page 33)
2 more points management made on revenue & sales performance
Profitability & Margins
See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The presentation highlights significant investments in capacity expansion over the past five years to improve asset utilization and operational efficiency (Page 7).
- Capacity expansion efforts have supported increased revenues and stronger product mix (Page 6).
- The company emphasizes continuing capacity expansion and higher utilization to drive sustainable margin improvement in upcoming quarters (Page 7).
- Strategic expansion plan includes pursuing selective inorganic growth opportunities alongside disciplined capital expenditure to strengthen product portfolio and market presence (Page 7).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Anuh Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹202 Cr, net profit ₹12 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Anuh Pharma Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- NGL Fine Chem Ltd (Q3 FY26)
Quarterly Revenue (Q3FY26):** ₹127.51 crores . Key investor presentation takeaways from NGL Fine Chem Ltd's Q3 FY26 investor presentation — and how it ranks aga
- Shree Ganesh Remedies Ltd (Q3 FY26)
Q3FY26 Revenue from Operations: ₹21.11 Cr . Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q3 FY26 investor presentation — and how it rank
- Bharat Parenterals Ltd (Q3 FY26)
Q3 FY26 Revenue from Operations (Consolidated): ₹65.2 crore, down 10% YoY from ₹72.3 crore in Q3 FY25 (Page 9). Key investor presentation takeaways from Bharat
- Themis Medicare Ltd (Q3 FY26)
90.13 Cr, a 3.9% decline year-on-year from Rs. Key investor presentation takeaways from Themis Medicare Ltd's Q3 FY26 investor presentation — and how it ranks a
Frequently Asked Questions
What were Anuh Pharma Ltd Q3 FY26 results?
Q3 FY26 Revenue: ₹201.18 Cr (page 13: Operating Revenue 197.18 + possibly rounding difference clarified on page 6 as ₹201 Cr) - Q3 FY25 Revenue: Not explicitly stated for Q3 FY25, but 9M FY25 total was ₹463.38 Cr (page 13) - Q3 FY26 vs Q3 FY25 Year-on-Year (YoY) % change not explicitly stated, but 9M FY26 revenue increased by 22.91% YoY to ₹569.54 Cr from ₹463.38 Cr (page 13) - Quarter-on-Quarter (QoQ) revenue growth from Q2 FY26 to Q3 FY26: 6.08% (₹197.18 Cr to ₹201.18 Cr) (page 13, page 6) - Outlook: Company anticipates steady growth rate of 15-16% per annum (page 33) - Commentary (page 6): "Revenue sustained strong momentum" and outlook expects year-end as per budget estimates with improving pricing, capacity expansion, higher utilization, and operational efficiencies driving sustainable margin improvements (pages 6 & 7). EBITDA (Q3 FY26): ₹20.91 Cr, up 62.63% QoQ (from ₹12.86 Cr) - Operating Margin (Q3 FY26): 23.28% (stated on Page 6), compared to 22.24% in the previous quarter - Profit After Tax (PAT, Q3 FY26): ₹13.45 Cr, up 76.70% QoQ (from ₹7.61 Cr) - Year-on-Year (9M FY26 vs 9M FY25) figures (Page 13): - EBITDA down 5.66% YoY to ₹47.45 Cr (from ₹50.29 Cr) - PAT down 15.85% YoY to ₹29.36 Cr (from ₹34.89 Cr) - Explicit Margin Outlook (Page 7 & 34): - Expectation of sustainable margin improvement driven by capacity expansion, higher utilization, operational efficiencies, improved pricing, and cost optimization.
What is Anuh Pharma Ltd share price analysis?
Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.
Is Anuh Pharma Ltd planning capital expenditure?
The presentation highlights significant investments in capacity expansion over the past five years to improve asset utilization and operational efficiency (Page 7).
Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.